التفاصيل البيبلوغرافية
| العنوان: |
Iron supplementation therapy in end-stage renal disease, hemodialysis patients: a clinical trial ; Suplementação de ferro em pacientes com insuficiência renal crônica em hemodiálise: um ensaio clínico |
| المؤلفون: |
Deferrari, Rafael, M. de Souza, Rafael, Karohl, Cristina, G. Barros, Elvino José, S. . Thomé, Fernando |
| المصدر: |
Clinical & Biomedical Research; Vol. 20 No. 3 (2000): Revista HCPA ; Clinical and Biomedical Research; v. 20 n. 3 (2000): Revista HCPA ; 2357-9730 |
| بيانات النشر: |
HCPA/FAMED/UFRGS |
| سنة النشر: |
2022 |
| المجموعة: |
SEER UFRGS (Universidade Federal do Rio Grande do Sul: Sistema Eletrônico de Editoração de Periódic) |
| مصطلحات موضوعية: |
Anemia, insuficiência renal crônica, suplementação de ferro, eritropoetina, hemodiálise, end-stage renal disease, iron therapy, erythropoietin, hemodialysis |
| الوصف: |
OBJECTIVE: To evaluate iron deficiency and to compare effectiveness of oral and parenteral iron supplementation in end-stage renal disease, hemodialysis patients.PATIENTS AND METHODS: Thirty-nine end-stage renal disease, hemodialysis patients were evaluated for age; weight; etiology of chronic renal failure; duration of hemodialysis; use of recombinant human erythropoietin; serum albumin, serum hemoglobin, hematocrit, and serum ferritin levels; and iron status. Iron status was assessed based on the following equation: [400 x log (serum ferritin) - log 30] - [150 x (11.55 - hemoglobin)] =iron status Patients were considered iron-deficient when the equation gave a negative result. Next, these patients were randomly divided into 2 groups. Patients with recent bleeding episodes or blood transfusion were excluded from the study. Group I received oral iron sulfate and group II intravenous iron hydroxide saccharate. The dosage was calculated basedon the iron status and body weight and adjusted for estimated bioavailability. RESULTS: Twenty-four (62%) patients were iron-deficient, out of which 19 completed the trial (11 patients in group I and 8 in group II). In the comparison with baseline values, group II had a significant increase in hematocrit (3.25 ± 3.69%, P < 0.05), serum hemoglobin (0.98 ± 0.86 g/dl, P < 0.02), serum ferritin (245 ± 133 ng/ml, P <0.01) and iron status (316.20 ± 214.230 mg, P < 0.01), whereas group I did not. In the comparison of group I and group II, the latter indicated greater increase in hematocrit, serum hemoglobin, serum ferritin and iron status (P < 0.05). Group II patients not using erythropoietin (5 of 8 patients), when compared to Group I, presented a greater increase in serum hemoglobin (0.8 ± 0.6 g/dl) and hematocrit (2.2± 3.4 %, P < 0.05). CONCLUSIONS: Considering equivalent dosages, intravenous iron therapy was more effective than oral therapy in increasing hematocrit, serum hemoglobin, serum ferritin, and iron status in hemodialysis patients with chronic renal ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
Portuguese |
| العلاقة: |
https://seer.ufrgs.br/index.php/hcpa/article/view/125379/85232Test; https://seer.ufrgs.br/index.php/hcpa/article/view/125379Test |
| الإتاحة: |
https://seer.ufrgs.br/index.php/hcpa/article/view/125379Test |
| حقوق: |
http://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.97E0E23D |
| قاعدة البيانات: |
BASE |
